Departments, Centers, & Programs:
55 Fruit Street
Boston, MA 02114-2696
- MD, Medizinische Hochschule
- Residency, Medizinische Hochschule
- Fellowship, Massachusetts General Hospital
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Jueppner studies the regulation of calcium and phosphate homeostasis. After joining the Endocrine Unit in 1986, he worked on the characterization and then the molecular cloning of the PTH/PTHrP receptor (PTHR1) through an expression cloning approach. Besides characterizing this G protein-coupled receptor extensively, additional investigations focused on defining inherited human disorders associated with an abnormal regulation of mineral ion homeostasis and bone metabolism. In addition to determining the molecular cause of Jansen’s metaphyseal chondrodysplasia, infantile cortical hyperostosis, and different forms of hypo- and hyperphosphatemia, his efforts led to the discovery of microdeletions within or up-stream of the GNAS locus as the cause of autosomal dominant pseudohypoparathyroidism type Ib (PHP-Ib) and to the discovery of homozygous or compound heterozygous mutations in NPT2c (also referred to as NaPi-IIc) as the cause of hereditary hypophosphatemic rickets with hypercalciuria (HHRH). He developed the first murine model of PHP-Ib and tested in vivo the effect of different PTH analogs on phosphate homeostasis and Npt2a/c expression. For example, he showed that the acute phosphaturic actions of PTH are mediated through the cAMP/PKA pathway, while the long-term regulation of renal phosphate handling requires the IP3/PKC signaling pathway. Dr. Jueppner developed one of the first assays for the measurement of FGF23, which was used for evaluating the role of this phosphaturic hormone in different disorders, particularly in patients with chronic kidney disease (CKD). He has expertise in the measurement of PTH through different immunoassays and using these measurements for predicting bone disease in CKD patients.
- Jüppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr., Kronenberg HM, Segre GV. A G protein-linked PTH/PTHrP receptor. Science. 1991;254:1024.
- Schipani E, Kruse K, Jüppner H. A mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science. 1995;268:98.
- Bastepe M, Fröhlich LF, Linglart A, Abu-Zahra H, Tojo K, Ward LM, Jüppner H. Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat. Genet. 2005;37:25.
- Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, Carpenter TO, Anderson D, Garabédian M, Sermet I, Fujiwara TM, Morgan KN, Tenenhouse HS, Jüppner H. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Am. J. Human Genet. 2006;78:179.
- Mannstadt M, Bertrand G, Muresan M, Weryha G, Leheup B, Pulusani SR, Grandchamp B, Jüppner H, Silve C. GCMB mutations cause an autosomal dominant form of hypoparathyroidism. J. Clin. Endocrinol. Metab. 2008;93:3568.
- Mannstadt M, Harris M, Bravenboer B, Chitturi S, Dreijerink KMA, Lambright DG, Lim ET, Daly MJ, Gabriel S, Jüppner H. Germline mutations affecting Ga11 in hypoparathyroidism. New Engl. J. Med. 2013;368:2532.
- Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren Ö, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H. FGF23 in oncogenic osteomalacia and X-linked hypophosphatemia. New Engl. J. Med. 2003;348:1656.